Skip to main content


Latest articles

25-07-2019 | Rheumatology | News | Article

FINCH 2: Further evidence for filgotinib as a treatment option for RA

Rheumatoid arthritis (RA) patients with an inadequate response or intolerance to biologic DMARDs who are treated with the selective JAK1 inhibitor filgotinib are more likely to achieve a clinical response than those given placebo, phase III trial results suggest.

24-07-2019 | Rheumatology | News | Article

EULAR issues updated guidance for managing large vessel vasculitis

EULAR has released updated recommendations for the management of large vessel vasculitis, including giant cell arteritis and Takayasu arteritis.

24-07-2019 | Rheumatology | News | Article

Success of etanercept withdrawal linked to pre-withdrawal remission status

The likelihood of maintaining remission following etanercept withdrawal is highest among rheumatoid arthritis patients with the greatest degree of remission prior to the start of withdrawal and decreases with decreasing remission status, research shows.

23-07-2019 | Rheumatology | News | Article

Low IGF1 levels predict CV risk in RA patients

Low levels of insulin-like growth factor 1 are associated with increased rates of cardiovascular events among women with rheumatoid arthritis, researchers report.

22-07-2019 | Rheumatology | News | Article

Partial knee replacement recommended for medial compartment osteoarthritis

Partial knee replacement is more cost-effective than total knee replacement over 5 years for patients with late-stage isolated medial compartment osteoarthritis of the knee, show results of the TOPKAT trial published in The Lancet.

19-07-2019 | Rheumatology | News | Article

Genetic loci influencing asymptomatic hyperuricemia to gout progression identified

A Japanese genome-wide association study has identified novel genetic loci associated with the susceptibility of gout in individuals with asymptomatic hyperuricemia.

18-07-2019 | Rheumatology | News | Article

Surrogate randomization technique enables triple biologic comparison

Estimated remission and retention rates do not differ significantly among patients with rheumatoid arthritis treated with either certolizumab pegol, abatacept, or biosimilar infliximab, show the results of a surrogate randomized controlled trial.

17-07-2019 | Rheumatology | News | Article

Mild tapering of TNF inhibitors may be appropriate in axSpA

Real-world study results suggest that mild tapering of tumor necrosis factor inhibitors does not influence the probability of achieving inactive disease among patients with axial spondyloarthritis.

15-07-2019 | Rheumatology | News | Article

Vitamin D has potential benefits for people with osteoarthritis

Vitamin D intake is inversely associated with cartilage degeneration among patients with osteoarthritis, and supplementation may have a protective effect, suggests an analysis of data from the Osteoarthritis Initiative.

12-07-2019 | Rheumatology | News | Article

SELECT COMPARE: Upadacitinib outperforms placebo and adalimumab in RA

Rheumatoid arthritis (RA) patients treated with the JAK1 selective inhibitor upadacitinib experience greater improvement in the signs and symptoms of disease than those given placebo or adalimumab, indicate findings from the SELECT COMPARE trial.

11-07-2019 | Rheumatology | News | Article

Biologic therapy has paved the way for improved outcomes in JIA

The biologic treatment era has led to “remarkable prognostic improvement,” relative to the methotrexate era, for children with juvenile idiopathic arthritis, show data reported in Arthritis Research & Therapy.

10-07-2019 | Rheumatology | News | Article

Biologic treatment may improve control of PsA-related bone disease

Psoriatic arthritis patients treated with biologic DMARDs have higher bone mass and strength than those not receiving DMARD treatment, suggest findings from a cross-sectional study.

09-07-2019 | Rheumatology | News | Article

Pregnancy outcomes improving for women with SLE

In the past two decades pregnancy outcomes, including in-hospital maternal mortality, have improved among women with systemic lupus erythematosus, but further improvements are needed to reduce risks further, US research shows.

08-07-2019 | Rheumatology | News | Article

RA genetic risk linked to IQ, hyperactivity during childhood

Genetic liability for rheumatoid arthritis is associated with lower IQ and symptoms of hyperactivity and inattention during childhood and adolescence, supporting a link between genetic risk for the condition and neural phenotypes, UK researchers report.

05-07-2019 | Rheumatology | News | Article

Favorable results with TNF inhibitors in Behçet's disease-associated uveitis

The tumor necrosis factor inhibitors adalimumab and infliximab both show good efficacy when used as first biologic agents in patients with refractory uveitis due to Behçet's disease, Spanish research shows.

04-07-2019 | Rheumatology | News | Article

Baricitinib, with optional methotrexate, may be beneficial in RA

Baricitinib monotherapy may be a suitable maintenance strategy for some patients with rheumatoid arthritis, but some may also need methotrexate, suggest findings from a post-hoc analysis.

03-07-2019 | Rheumatology | News | Article

Tanezumab shows analgesic benefits in OA but at a cost

Findings from a phase III trial conducted in the USA suggest that tanezumab improves pain and physical function scores relative to placebo among patients with moderate-to-severe hip or knee osteoarthritis and an inadequate response to analgesics.

02-07-2019 | Rheumatology | News | Article

Support for TNF inhibitor use in patients with entero-Behçet’s disease

People with entero-Behçet’s disease and active ulcerative lesions who are treated with tumor necrosis factor inhibitors, either alone or in combination with corticosteroids, are more likely to experience ulcer cure or improvement than those taking corticosteroids alone, researchers report.

01-07-2019 | Rheumatology | News | Article

OA patients at increased risk for multiple comorbidities

People with osteoarthritis are significantly more likely than those without to have multiple comorbidities, particularly stroke, peptic ulcers, and the metabolic syndrome, show results of a systematic review and meta-analysis of observational data.

28-06-2019 | Rheumatology | News | Article

Glucocorticoid withdrawal an achievable goal in patients with SLE

Glucocorticoid tapering and complete withdrawal can be achieved in patients with systemic lupus erythematosus and may be particularly successful in those with long-term remission or low disease activity, Italian researchers report.

Image Credits